Lexaria Reaches Patent Milestone - 50 Patents Now Granted Worldwide
- Achievement of 50 worldwide patents milestone strengthens intellectual property portfolio
- New Australian patent for epilepsy treatment extends protection until 2044
- New Japanese patent for sublingual nicotine delivery valid until 2043
- Company positioned to target large markets: epilepsy ($15B by 2032) and oral nicotine (26% annual growth)
- Strategic partnership with Altria Ventures Inc. for nicotine products
- None.
Insights
Lexaria strengthens its patent portfolio to 50 patents worldwide, enhancing commercial potential in billion-dollar epilepsy and nicotine markets.
Lexaria has achieved a significant intellectual property milestone with 50 granted patents worldwide, following two new international patent approvals. This patent expansion strategically strengthens the company's competitive moat for its DehydraTECH™ drug delivery platform across multiple high-value markets.
The new Australian patent for epilepsy treatments extends protection until 2044, complementing Lexaria's existing 6 U.S. patents in this space. This positions the company to potentially capture value in the epilepsy drug market, which was valued at
Similarly, the Japanese patent for sublingual nicotine delivery (expiring 2043) enhances Lexaria's position in the
This patent milestone represents the execution of a decade-long IP strategy and potentially increases Lexaria's attractiveness for pharmaceutical industry partnerships. The company already has established relationships in the nicotine space, with Altria Ventures Inc. holding a
These patent approvals extend Lexaria's exclusivity periods well into the 2040s, providing long-term protection for their technology platform while they pursue commercialization in substantial markets.
New patents received for the treatment of epilepsy and for the sublingual delivery of nicotine
KELOWNA, BC / ACCESS Newswire / June 23, 2025 / Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms, is pleased to announce that it has received 2 new international patents. This now brings Lexaria's total worldwide patent portfolio to 50.
"We are pleased to announce the addition of these patents as we continue to execute on our strategy to broaden Lexaria's patent portfolio. We believe that this not only increases our likelihood of entering into commercial deals within the pharmaceutical industry, but that it also serves as an important building block for establishing and protecting long-term value for our shareholders and all stakeholders," said Rich Christopher, CEO of Lexaria. "The achievement of 50 worldwide patents marks the accomplishment of a milestone that had been envisioned by the Company's management for over a decade."
Lexaria has been granted a new patent in Australia within its patent family #24, Compositions and Methods for Treating Epilepsy. This broadens Lexaria's intellectual property protection for the use of its DehydraTECH™ enhanced processing technology related to the treatment of epilepsy outside of the USA, where a strong patent portfolio of 6 existing patents has already been built. This new patent will expire in 2044.
Lexaria has also been granted a new patent in Japan within its patent family #20, Compositions and Methods for Sublingual Delivery of Nicotine. This patent joins already-existing patents within the same family in both the USA and Canada. This new patent will expire in 2043.
The epilepsy drug market was US
The global retail oral nicotine market was valued at US
About Lexaria Bioscience Corp. & DehydraTECH
DehydraTECH™ is Lexaria's patented drug delivery formulation and processing platform technology which improves the way active pharmaceutical ingredients enter the bloodstream through oral delivery. Lexaria has developed and investigated DehydraTECH with a variety of beneficial molecules in oral formats. DehydraTECH has repeatedly demonstrated the ability to increase bio-absorption and has also evidenced an ability to deliver some drugs more effectively across the blood brain barrier. Lexaria operates a licensed in-house research laboratory and holds a robust intellectual property portfolio with 50 patents granted and additional patents pending worldwide. For more information, please visit www.lexariabioscience.com.
CAUTION REGARDING FORWARD-LOOKING STATEMENTS
This press release includes forward-looking statements. Statements as such term is defined under applicable securities laws. These statements may be identified by words such as "anticipate," "if," "believe," "plan," "estimate," "expect," "intend," "may," "could," "should," "will," and other similar expressions. Such forward-looking statements in this press release include, but are not limited to, statements by the company relating the Company's ability to carry out research initiatives, receive regulatory approvals or grants or experience positive effects or results from any research or study. Such forward-looking statements are estimates reflecting the Company's best judgment based upon current information and involve a number of risks and uncertainties, and there can be no assurance that the Company will actually achieve the plans, intentions, or expectations disclosed in these forward-looking statements. As such, you should not place undue reliance on these forward-looking statements. Factors which could cause actual results to differ materially from those estimated by the Company include, but are not limited to, government regulation and regulatory approvals, managing and maintaining growth, the effect of adverse publicity, litigation, competition, scientific discovery, the patent application and approval process, potential adverse effects arising from the testing or use of products utilizing the DehydraTECH technology, the Company's ability to maintain existing collaborations and realize the benefits thereof, delays or cancellations of planned R&D that could occur related to pandemics or for other reasons, and other factors which may be identified from time to time in the Company's public announcements and periodic filings with the US Securities and Exchange Commission on EDGAR. The Company provides links to third-party websites only as a courtesy to readers and disclaims any responsibility for the thoroughness, accuracy or timeliness of information at third-party websites. There is no assurance that any of Lexaria's postulated uses, benefits, or advantages for the patented and patent-pending technology will in fact be realized in any manner or in any part. No statement herein has been evaluated by the Food and Drug Administration (FDA). Lexaria-associated products are not intended to diagnose, treat, cure or prevent any disease. Any forward-looking statements contained in this release speak only as of the date hereof, and the Company expressly disclaims any obligation to update any forward-looking statements or links to third-party websites contained herein, whether as a result of any new information, future events, changed circumstances or otherwise, except as otherwise required by law.
INVESTOR CONTACT:
George Jurcic - Head of Investor Relations
ir@lexariabioscience.com
Phone: 250-765-6424, ext 202
SOURCE: Lexaria Bioscience Corp.
View the original press release on ACCESS Newswire
FAQ
How many patents does Lexaria Bioscience (LEXX) now have worldwide?
What are the new patents granted to Lexaria (LEXX) in 2025?
What is the market size for epilepsy drugs that Lexaria (LEXX) is targeting?
What is Altria Ventures' relationship with Lexaria (LEXX)?
What is the projected growth of the oral nicotine market that Lexaria (LEXX) operates in?
